CFTR and cystic fibrosis: With increasingly milder CF disease in paediatric and adult patients and the licencing of CFTR modulators for infants as young as 1 month who may have no clinical symptoms or abnormal lung function tests, there is a need for sensitive outcome measures that can detect early structural lung changes for both clinical trials and routine clinical follow-up.